Latest News and Press Releases
Want to stay updated on the latest news?
-
OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
-
OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
-
OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
-
OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of...
-
OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
-
VTP-300 作為單藥治療和與單次給藥的低劑量納武利單抗聯合使用時，沒有出現與治療相關的嚴重不良事件和罕見的短暫性轉氨酶升高。 在一些接受 VTP-300 作為單藥治療或與單次低劑量納武利單抗作加強劑量聯合治療的患者中，可觀察到乙型肝炎表面抗原 (HBsAg) 顯著和持久降低。在乙型肝炎表面抗原基線較低的患者中，下降最為顯著。 所有接受 VTP-300...
-
VTP-300을 단일요법으로, 또는 저용량의 니볼루맙을 1회 함께 투여했을 때, 치료를 요하는 위중한 부작용은 나타나지 않았으며, 낮은 확률로 발현된 아미노전이염은 일시적이었음. VTP-300을 단일요법으로, 또는 2차 접종 시 저용량의 니볼루맙을 1회 함께 투여했을 때, 일부 환자에게서 유의미하고 지속적인 B형 간염 표면항원(HBsAg) 감소...
-
VTP-300无论是作为一种单药，或是与一种低剂量纳武单药给药联合使用，均未出现与治疗相关的严重不良事件和罕见的短暂性转氨酶升高现象。 在接受VTP-300作为单药治疗或在增强剂量下与单一低剂量纳武联合使用的一些患者中，可以看到乙型肝炎表面抗原（HBsAg）呈现有意义且持久减少。在HBsAg基准较低的患者中，下降最为突出。 ...
-
VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient...
-
OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...